Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 91,918,800
  • Shares Outstanding, K 2,532,896
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.55
  • Price/Sales 4.32
  • Price/Cash Flow 10.87
  • Price/Book 6.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.76
  • Number of Estimates 3
  • High Estimate 0.85
  • Low Estimate 0.71
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -41.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.42 +3.18%
on 01/14/19
39.38 -7.19%
on 01/04/19
-1.68 (-4.39%)
since 12/18/18
3-Month
35.42 +3.18%
on 01/14/19
41.78 -12.51%
on 11/13/18
-2.40 (-6.16%)
since 10/18/18
52-Week
32.69 +11.81%
on 03/01/18
41.78 -12.51%
on 11/13/18
+1.48 (+4.22%)
since 01/18/18

Most Recent Stories

More News
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

KTOV : 1.33 (-7.64%)
AZN : 36.55 (+0.72%)
LLY : 116.59 (-2.16%)
RHHBY : 32.6100 (+0.59%)
PFE : 42.53 (+0.14%)
BMY : 50.12 (+1.05%)
SNY : 41.48 (-1.36%)
Immunomedics Gets CRL From FDA for Breast Cancer Candidate

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

AZN : 36.55 (+0.72%)
CLVS : 24.00 (+7.29%)
RHHBY : 32.6100 (+0.59%)
IMMU : 13.31 (-26.42%)
NVS or AZN: Which Is the Better Value Stock Right Now?

NVS vs. AZN: Which Stock Is the Better Value Option?

AZN : 36.55 (+0.72%)
NVS : 88.99 (+0.41%)
Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C

MYL : 29.59 (+0.14%)
IRWD : 12.91 (-1.53%)
AZN : 36.55 (+0.72%)
AGN : 160.22 (+2.34%)
What's in Store for Merck in 2019 After a Solid Run in '18?

Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.

AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
INCY : 78.42 (-0.32%)
AMGN : 203.88 (+0.97%)
Moderna (MRNA) Announces Pipeline Progress, Shares Rise

Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
VRTX : 194.70 (+2.19%)
MRNA : 16.69 (+2.33%)
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff

Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.

IRWD : 12.91 (-1.53%)
AZN : 36.55 (+0.72%)
AGN : 160.22 (+2.34%)
TAK : 19.78 (+0.76%)
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
PJP : 66.54 (+0.71%)
IHE : 147.48 (+0.46%)
PPH : 58.09 (+0.71%)
PFE : 42.53 (+0.14%)
Sosei Heptares to Receive US$15 Million Milestone Payment From AstraZeneca With First Partnered Program Moving Towards Phase 2

TOKYO and LONDON, January 7, 2019 /PRNewswire/ --

AZN : 36.55 (+0.72%)
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate

Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

CELG : 86.27 (-0.37%)
AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
LLY : 116.59 (-2.16%)
ABBV : 89.50 (+2.64%)
PFE : 42.53 (+0.14%)
BMY : 50.12 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 37.09
1st Resistance Point 36.82
Last Price 36.55
1st Support Level 36.30
2nd Support Level 36.05

See More

52-Week High 41.78
Fibonacci 61.8% 38.30
Fibonacci 50% 37.23
Last Price 36.55
Fibonacci 38.2% 36.16
52-Week Low 32.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar